Pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia - Biologic Drug Details

Summary for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Standardized Pollen Allergenic Extract Non-Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Derived from Patent Text Search

No patents found based on company disclosures

Pollens - weeds and garden plants, ragweed, short ambrosia artemisiifolia Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Biologic Drugs: The Impact of Pollens, Weeds, and Garden Plants, Specifically Ragweed (Ambrosia artemisiifolia)

Introduction

The biologics market is on a significant growth trajectory, driven by various factors including the increasing burden of chronic diseases, technological advancements, and the rising adoption of biosimilars. However, the impact of environmental factors such as pollens from weeds and garden plants, particularly ragweed (Ambrosia artemisiifolia), on this market is multifaceted and warrants a detailed examination.

Biologics Market Overview

The biologics market has seen substantial growth in recent years. As of 2023, the market size was valued at USD 349.6 billion, and it is projected to reach USD 699.5 billion by 2032, growing at a CAGR of 7.8% during the forecast period[1][4].

Drivers of the Biologics Market

Several key factors are driving the expansion of the biologics market:

• Increasing Burden of Chronic Diseases: The rising prevalence of chronic diseases such as autoimmune disorders, cancer, and inflammatory diseases is a major driver.
• Technological Advancements: Continuous innovations in drug delivery systems and the development of targeted therapies are significant contributors.
• Growing Adoption of Biosimilars: The increasing acceptance and use of biosimilars are reducing costs and expanding access to biologic treatments.
• Strong Pipeline of Biologic Drugs: The approval of novel biologic treatments, including gene therapy, antisense, and RNAi therapies, is expected to drive market growth[1][4].

Impact of Ragweed on Health and Economy

Ragweed, particularly Ambrosia artemisiifolia, has significant health and economic implications:

• Health Impacts: Ragweed pollen is a leading cause of hay fever and a major trigger of asthma. The health costs associated with ragweed allergies are substantial, with estimated medical care costs ranging between €59 million and €186 million annually in some regions[3].
• Economic Impacts: Beyond health costs, ragweed also affects agricultural productivity. In the European Union, economic losses due to reduced agricultural production caused by ragweed were estimated at €1846 million per year in 2011[3].

Climate Change and Ragweed Distribution

Climate change is altering the distribution and growth patterns of ragweed:

• Expansion and Contraction: Studies predict that while ragweed will contract in certain areas like central Florida and the southern Appalachian Mountains, it will expand in the northeastern United States by mid-century. This expansion is driven by factors such as increased CO2 levels, which enhance ragweed's growth and pollen production[2].
• Health and Agricultural Implications: The projected expansion of ragweed will likely increase allergy-related health issues and further impact agricultural yields, particularly in regions where sunflowers and other related crops are grown[2][3].

Biologic Therapies for Allergies

Given the increasing burden of allergies caused by ragweed and other allergenic plants, the demand for biologic therapies is on the rise:

• Allergy Treatments: Biologics are being developed to treat severe allergies, including those caused by ragweed pollen. These treatments often involve targeted therapies that reduce the immune system's response to allergens.
• Market Potential: The growing need for effective allergy treatments presents a significant market opportunity for biologic drugs. As the prevalence of allergies increases due to environmental changes, the demand for these therapies is expected to rise accordingly[1][4].

Financial Trajectory

The financial trajectory of the biologics market, influenced by the factors mentioned above, is promising:

• Market Size Projections: The market is expected to grow from USD 349.6 billion in 2023 to USD 699.5 billion by 2032, with a CAGR of 7.8%[1].
• Investment and R&D: Significant investments in R&D and the strong pipeline of biologic drugs are key drivers of this growth. The increasing adoption of biosimilars and the loss of patent exclusivity for leading biologic drugs also contribute to market expansion[1][4].

Regulatory Approvals and Reimbursement

Regulatory approvals and favorable reimbursement policies are crucial for the biologics market:

• Regulatory Environment: The escalating approvals of biologics by regulatory agencies are a significant driver of market growth. Favorable reimbursement rules in many regions further support the adoption of these therapies[1].
• Impact on Market Growth: These factors ensure that biologic treatments remain accessible and affordable, which in turn drives market growth and innovation[1][4].

Conclusion

The biologics market is poised for significant growth, driven by a combination of technological advancements, increasing chronic disease prevalence, and the growing adoption of biosimilars. The impact of ragweed and other allergenic plants on health and the economy underscores the need for effective biologic therapies. As climate change continues to alter the distribution and growth patterns of ragweed, the demand for these therapies is likely to increase, presenting both challenges and opportunities for the biologics market.

Key Takeaways

• The biologics market is expected to reach USD 699.5 billion by 2032, growing at a CAGR of 7.8%.
• Ragweed pollen significantly impacts health and agriculture, with substantial economic costs.
• Climate change is altering the distribution of ragweed, leading to increased allergy-related health issues.
• Biologic therapies for allergies are a growing market segment.
• Regulatory approvals and favorable reimbursement policies are crucial for market growth.

FAQs

What is the projected growth rate of the biologics market from 2024 to 2032?

The biologics market is expected to grow at a CAGR of 7.8% from 2024 to 2032[1].

How does ragweed impact agricultural productivity?

Ragweed competes with crops like sunflowers for resources, leading to reduced agricultural yields and significant economic losses, estimated at €1846 million per year in the European Union[3].

What are the health costs associated with ragweed allergies?

The health costs associated with ragweed allergies can range between €59 million and €186 million annually, depending on the region[3].

How does climate change affect the distribution of ragweed?

Climate change is expected to expand the distribution of ragweed in the northeastern United States by mid-century, while contracting it in areas like central Florida and the southern Appalachian Mountains[2].

What role do biologic therapies play in treating allergies caused by ragweed?

Biologic therapies are being developed to treat severe allergies, including those caused by ragweed pollen, by reducing the immune system's response to allergens[1][4].

Sources

1. Biologics Market Size to Reach USD 699.5 Billion by 2032, Impelled by Emergence of Advanced Drug Delivery Systems. Biospace.
2. Climate change impacts on the distribution of the allergenic plant, common ragweed (Ambrosia artemisiifolia) in the eastern United States. PLOS ONE.
3. Ragweed, an invasive plant that is problematic for both health and agriculture. ANSES.
4. Biologics Market - Size, Growth, Share & Report. Mordor Intelligence.